



HAL
open science

Proteomics Analysis of Formalin Fixed Paraffin Embedded Tissues in the Investigation of Prostate Cancer

Anna Mantsiou, Manousos Makridakis, Konstantinos Fasoulakis, Ioannis Katafigiotis, Constantinos A Constantinides, Jerome Zoidakis, Maria G Roubelakis, Antonia Vlahou, Vasiliki Lygirou

► **To cite this version:**

Anna Mantsiou, Manousos Makridakis, Konstantinos Fasoulakis, Ioannis Katafigiotis, Constantinos A Constantinides, et al.. Proteomics Analysis of Formalin Fixed Paraffin Embedded Tissues in the Investigation of Prostate Cancer. *Journal of Proteome Research*, 2020, 19 (7), pp.2631-2642. 10.1021/acs.jproteome.9b00587 . hal-03024216

HAL Id: hal-03024216

<https://hal.science/hal-03024216v1>

Submitted on 25 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Proteomics analysis of Formalin Fixed Paraffin Embedded tissues in the investigation of prostate cancer

Anna Mantsiou, Manousos Makridakis, Konstantinos Fasoulakis, Ioannis Katafigiotis, Constantinos A. Constantinides, Jerome Zoidakis, Maria G. Roubelakis, Antonia Vlahou, and Vasiliki Lygirou

J. Proteome Res., **Just Accepted Manuscript** • DOI: 10.1021/acs.jproteome.9b00587 • Publication Date (Web): 04 Nov 2019

Downloaded from pubs.acs.org on November 5, 2019

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3 1 **Title: Proteomics analysis of Formalin Fixed Paraffin Embedded tissues in the investigation of**
4 **prostate cancer**
5 2

6
7 3 **Anna Mantsiou, Manousos Makridakis, Konstantinos Fasoulakis, Ioannis Katafigiotis, Constantinos A. Constantinides,**
8 4 **Jerome Zoidakis, Maria G. Roubelakis, Antonia Vlahou and Vasiliki Lygirou**
9 5

10
11
12 6 **Abstract**

13 7 Prostate cancer (PCa) is one of the leading causes of death in men worldwide. The molecular features, associated
14 8 with the onset and progression of the disease, are under vigorous investigation. Formalin-fixed paraffin-
15 9 embedded (FFPE) tissues are valuable resources for large-scale studies, however, their application in proteomics
16 10 is limited due to protein cross-linking. In this study, the adjustment of a protocol for the proteomic analysis of
17 11 FFPE tissues was performed which was followed by a pilot application on FFPE PCa clinical samples to investigate
18 12 whether the optimized protocol can provide biologically relevant data for the investigation of PCa. For the
19 13 optimization, FFPE mouse tissues were processed using ~~eight~~ seven protein extraction protocols including
20 14 combinations of homogenization methods (beads, sonication, boiling) and buffers (SDS based and Urea-
21 15 Thiourea based). The proteome extraction efficiency was then evaluated based on protein identifications and
22 16 reproducibility using SDS electrophoresis and high resolution LC-MS/MS analysis. Comparison between the FFPE
23 17 and matched fresh frozen (FF) tissues, using an optimized protocol involving protein extraction with an SDS-
24 18 based buffer following beads homogenization and boiling, showed a substantial overlap in protein
25 19 identifications (~~1106 common between the 1214 identified in FF and 1249 identified in FFPE~~) with a strong
26 20 correlation in relative abundances ($r_s=0.7820.819$, $p<0.001$). Next, FFPE tissues (3 sections, 15 μ m each per
27 21 sample) from 10 patients with PCa corresponding to tumor (GS=6 or GS \geq 8) and adjacent benign regions were
28 22 processed with the optimized protocol. Extracted proteins were analyzed by GeLC-MS/MS followed by statistical
29 23 and bioinformatics analysis. Proteins significantly deregulated between PCa GS \geq 8 and PCa GS=6 represented
30 24 extracellular matrix organisation, gluconeogenesis and phosphorylation pathways. Proteins deregulated
31 25 between cancerous ~~tissues~~ and adjacent benign ~~tissues-counterparts~~, showed reflected increased translation,
32 26 peptide synthesis and protein metabolism in the former, which is consistent ~~to~~ with the literature. In conclusion,
33 27 the results support the relevance of the proteomic findings in the context of PCa and the reliability of the
34 28 optimized protocol for proteomics analysis of FFPE material.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 29
52
53 30 **Keywords**

54
55 31 FFPE; Protocol adjustment; Prostate cancer; Proteomics; LC-MS/MS
56
57
58
59
60

1
2
3 32
4
5 33
6
7 34
8
9 35
10
11 36
12 37
13 38
14 39
15 40
16 41
17 42
18 43
19 44
20 45
21 46
22 47
23 48
24 49
25 50
26 51
27 52
28 53
29 54
30 55
31 56
32 57
33 58
34 59
35 60
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1. Introduction

Prostate cancer (PCa) ranks as the second most frequently diagnosed cancer and the fifth leading cause of cancer-related deaths in men's population worldwide, with 1.3 million new cases and 359,000 deaths in 2018 [1]. The major clinical challenge is the inability of current biomarker tests and stratification systems to reliably predict the disease outcome and distinguish the indolent from the highly aggressive PCa tumors [2]. Prostate-Specific Antigen (PSA) is currently the most widely used biomarker test for PCa diagnosis and prognosis. However, it has poor specificity [3] and consequently may lead to unnecessary biopsies and high rates of overdiagnosis and overtreatment. In the last decade, various molecular tests based on genetic markers have been FDA-approved by FDA for PCa diagnosis (SelectMDX, Progenisa) and prognosis (OncotypeDx, Prolaris, Decipher), however the lack of cost effectiveness combined with the suboptimal accuracy rates hinder their wide use [4]. Taking these into consideration, there is an emerging clinical need for PCa molecular biomarkers of high specificity and sensitivity that will assess more accurately the disease progression.

Even though main advancements in the characterization of PCa tissue at the DNA/RNA levels have been made, reflected in the current molecular subtyping schemes of the disease [5], large-scale proteomics studies with validated results remain scarce [6]. ~~information at the proteome level is still largely lacking.~~ In addition, The vast majority of the reported proteomics studies on PCa use have applied relatively low resolution proteomic technologies (2DE, 2D-DIGE, RPPA) which are semi-quantitative and provide inadequate proteomic coverage [6–8]. Nevertheless, the number of high resolution proteomics studies on PCa has risen in the last five years uncovering new insights on PCa progression [6,9,10].

Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks represent a valuable source of samples for clinical and translational research, as pathology departments routinely archive them in vast numbers. Tissue fixation routinely takes place in formalin solution (for 24-48 h) enabling the storage of samples in ambient condition for decades [11]. Extracting the molecular profile of FFPE tissues enables prospective and retrospective studies to be performed with adequate statistical power and could greatly facilitate biomarker discovery and validation. In addition, proteomic assessment of FFPE tissue samples can provide precious insights into the molecular mechanisms underlying the disease pathology and hence facilitating the discovery of novel drug targets [6]. Molecular assays for oncological prognosis have been already developed using FFPE tissue samples. Oncotype DX prostate cancer assay, which is a 17-gene RT-PCR assay predicting the aggressiveness of prostate cancer, is such an example [12].

1
2
3 63 The protein profiling of FFPE tissues is challenging due to the formalin-induced chemical modifications of
4 64 proteins [13,14]. The induced cross-linking decreases the protein solubility and inhibits its digestion by
5 65 preventing trypsin or other endopeptidases to reach their cleaving sites [15,16]. In addition, amino acid chemical
6 66 changes are frequently induced [11,16,17]. As a result, the proteomics output may be compromised. Since the
7
8 67 first reported effort ~~to optimize protein extraction from FFPE~~, in 1998, ~~to optimize protein extraction from FFPE~~,
9
10 68 using 2% SDS combined with sequential heating steps at 100 °C and 60 °C [18], it was not until 2005 that a
11
12 69 shotgun-based workflow for the analysis of FFPE tissue was proposed by Hood et al. [19], using human PCa
13
14 70 clinical samples. In this case, protein extraction relied on the use of a commercial kit and heating at 95 °C for 90
15
16 71 min. Upon analyzing the samples by label-based nano-RP-LC-MS/MS- about 1,000 proteins (702 proteins from
17
18 72 benign prostatic hyperplasia and 1,153 proteins from prostate carcinoma with 69 proteins being differentially
19
20 73 expressed between the two) were reported [19]. Since then, the studies that investigated the global ~~proteome~~
21
22 74 ~~proteomic~~ changes in PCa ~~FFPE samples~~ are scarce, using in some cases low resolution proteomics techniques
23
24 75 (2D Gel, MALDI TOF) or extensive fractionation and/or expensive labeling protocols [20–23].

25 76 Here we describe a simple and efficient protocol for proteomics analysis of FFPE tissue and demonstrate its
26
27 77 efficacy in providing biologically relevant information in the context of PCa through a pilot study, involving the
28
29 78 analysis of low versus high risk ~~prostate cancer~~PCa.
30
31 79

32 80 2. Materials and Methods

33 81 2.1 Tissue samples

34
35 82 ~~Archival~~FFPE mouse tissue samples, as per availability, [~~{~~kidney and liver; fixed in 10% v/v formalin in water
36
37 83 overnight, dehydrated in 70% ethanol, embedded in paraffin and stored at ~~room temperature (RT)]~~ were
38
39 84 employed for protocol optimization. In some cases, respective frozen tissue samples were also available.

40
41 85 Archival FFPE prostate tissue specimens from 10 patients ~~operated-who had undergone surgery~~ at the
42
43 86 Ippokrateio Hospital, Athens, were used in the study, in line to ethics requirements (the study was approved
44
45 87 from the Ethics Committee of the Medical School, National and Kapodistrian University of Athens, ~~-with~~ protocol
46
47 88 number 45/2018). The clinic~~o~~-pathological information associated ~~to-with~~ these specimens is provided in Table
48
49 89 S1. FFPE sections (4 μm) from each block were stained with hematoxylin/eosin and examined by the ~~Pathologist~~
50
51 90 ~~pathologist~~ to localize the site of the tumor and evaluate the Gleason grading. Then, tumor and benign regions
52
53 91 were collected by microdissection ~~excised~~ from the adjacent unstained sections. The samples used in the current
54
55 92 study corresponded to: Gleason Score (GS) 6 (3+3) cancerous tissue (n=4; referred to as 2a-5a) and ~~their~~-benign
56
57
58
59
60

93 ~~counterparts adjacent tissues~~ (n=5; referred to as 1b-5b); GS \geq 8 cancerous tissue (n=5; referred to 6a-10a) and
 94 ~~their benign adjacent tissues counterparts~~ (n=4; referred to as 6b-9b).

96 2.2 Protein extraction from FFPE and FF tissue with the optimized protocol

97 For each FFPE sample, 3 - 4 sections 15 - 20 μ m each were obtained and combined in a 2 ml eppendorf tube
 98 for further processing. This included, deparaffinization through three incubations in xylene (first two for 5 min
 99 each and the last for 1 min), each one followed by centrifugation for 3 min at 13,000 rpm, at ~~RT room~~
 100 ~~temperature (RT)~~. The sections were then rehydrated through a series of ethanol and distilled water washes
 101 (100% ethanol for 2 min, 95% ethanol for 1 min, 70% ethanol for 1 min, distilled water for 1 min), each one
 102 followed by centrifugation for 3 min at 13,000 rpm, at RT. Upon rehydration, the tissue pellets were left to air-
 103 dry for 30 min at RT. The subsequent steps were common for both FFPE and ~~fresh~~ frozen (FF) samples (without
 104 any prior steps for the latter). The samples were resuspended in 200 μ l of FASP buffer (pH \sim 8), containing 100
 105 mM Tris-HCl, 4 % SDS, 100 mM DTE. For homogenization, 0.9 - 2.0 mm stainless steel beads were added to the
 106 samples and placed at the bullet blender homogenizer (Bullet Blender Storm BBY24M, Next Advance, USA) in 2
 107 sequential steps: 5 min ~~in-at~~ speed 12 and 3 min ~~in-at~~ speed 10. The homogenates were sonicated for 3 cycles
 108 of 5 ~~seconds~~ each using a tip sonicator (36% power used), followed by 1 h of heating at 90 $^{\circ}$ C on a heating block.
 109 Then, the extracts were centrifuged for 10 min at 13,000 rpm at RT and the supernatants (\sim 170 μ l) were
 110 transferred ~~in-to~~ new 1.5 ml eppendorf tubes and protease inhibitors were added to a final concentration of
 111 3.6% and stored at -80 $^{\circ}$ C until use.

112 The extraction buffers that were tested during the optimization process include: PEB buffer (20 mM Tris-
 113 HCl, 200 mM DTE, 2% SDS, 20% Glycerol); Urea-Thiourea buffer (7 M Urea, 2 M Thiourea, 4% Chaps, 65 mM
 114 DTE, 2% IPG); ~~and FASP buffer (100 mM Tris-HCl, 4 % SDS, 100 mM DTE)~~ (Table 1).

115
 116 **Table 1.** Seven combinations of homogenization methods and extraction buffers were used for the FFPE
 117 extraction optimization

Homogenization means Extraction buffers	bullet blender	bullet blender, sonication	bullet blender, sonication, heating
PEB (20mM Tris-HCl, 200mM DTE, 2% SDS, 20% Glycerol)	✓		
Urea (7M Urea, 2M Thiourea, 4% Chaps, 65mM DTE, 2% IPG)	✓	✓	✗
FASP (100mM Tris-HCl pH 7.6, SDS 4%, 100mM DTE)	✓	✓	✓

FASP without SDS*

118 * FASP buffer is added initially without the SDS. SDS is added in final concentration 4% right before the heating step.

119

2.3 Protein digestion of FFPE prostate clinical tissues

120
121 The GeLC-MS method [24] was applied. Samples (protein extract from 3 – 4 sections 15 - 20 μm each, per
122 sample) were concentrated 10 times (using Amicon Ultra Centrifugal Filters, 3 kDa ~~MWCOMW~~ MW cut-off) with
123 buffer exchange in 50 mM ammonium bicarbonate, pH 8.5. The total amount of the concentrated sample (18 -
124 20 μl) was then loaded on the polyacrylamide gel and the rest of the protocol was followed exactly as described
125 in [24]. Trypsinization was performed by adding 600 ng of trypsin, for 12 - 16 h, at RT in the dark, in a humidified
126 container. Peptide extraction followed and the peptide solution was lyophilized [24].

127

2.4 LC-MS/MS analysis and MS data processing

128
129 LC-MS/MS analyses were performed on a Dionex Ultimate 3000 UHPLC nano flow system coupled to a
130 Thermo Q Exactive mass spectrometer and an Orbitrap Elite. Prior to the analysis, each sample was
131 reconstituted in 12 μl mobile phase A (0.1% Formic Acid, pH 3.5) and 6 μl loaded on the column. In all cases, raw
132 files were processed with Thermo Proteome Discoverer 1.4 software, utilizing the Sequest search engine and
133 the UniProt human ([downloaded on 16/12/2018 including 20243 reviewed entries](#)) and mouse ([downloaded on](#)
134 [22/11/2017 including 16935 reviewed entries](#)) fasta canonical data-bases (~~downloaded on 16/12/2018 including~~
135 ~~20243 reviewed entries~~). The search was performed using carbamidomethylation of cysteine as static and
136 oxidation of methionine as dynamic modifications. Two missed cleavage sites, a precursor mass tolerance of 10
137 ppm and fragment mass tolerance of 0.05 Da were allowed. For both the human and the mouse samples, the
138 filters used were as follows: Peptide: High Confidence (FDR q value based = 0.01) and Medium Confidence (FDR
139 q value based = 0.05), peptide rank: Maximum rank=1, peptide grouping: enabled, protein grouping: enabled.

140

2.5 Statistical analysis

141
142 The peak area of precursor ions was used to assess the relative abundance of the identified proteins (label
143 free method). Protein abundance in each sample was calculated as the sum of all peptide peak areas from the
144 extracted chromatogram, normalized as follows (ppm): Protein peak area/Total peak area per sample $\times 10^6$. For
145 the comparison between the cancerous tissues (GS6 and GS \geq 8; n=9) and the adjacent benign tissues (GS6 and
146 GS \geq 8; n=9), a threshold of 30% was applied (total number of samples n=18). For the rest of the comparisons,
147 due to the smaller sample size (n=4 or 5 per group) proteins detected in at least 60% of samples in at least one
148 group were considered for quantification and statistical analysis to increase reliability of results. The non-

1
2
3 149 parametric Mann-Whitney U- test (two tailed, unadjusted) was utilized for defining statistical significance. The
4
5 150 test was applied on each of the comparisons using SPSS software (IBM SPSS Statistics for Windows, Version 22.0.
6
7 151 Armonk, NY: IBM Corp. Released 2013). Fold change for each comparison ~~were~~was calculated as follows: mean
8
9 152 value of the case group / mean value of the control group. Proteins with a fold change of ≥ 1.5 (up-regulated) or
10
11 153 ≤ 0.67 (down-regulated) were considered as differentially expressed, whereas proteins that are significantly
12
13 154 differentially expressed are those that fulfilled both the ~~1.5~~ratio cutoffs and also have a p-value ≤ 0.05 from the
14
15 155 Mann-Whitney test.
16

157 **2.6 Pathway Bioinformatics analysis**

158 Pathway analysis was performed using the ClueGO plug-in in Cytoscape 3.5.1. Only the significantly
159 deregulated proteins were used as input and they were assigned into two separate lists according to their
160 regulation (up- or down- regulated in cases versus controls). Ontologies were retrieved from the REACTOME
161 pathway database (organism: Homo Sapiens, 2,240 terms with 10,664 available unique genes, updated on
162 March 18, 2019) and only statistically significant pathways (*Benjamini-Hochberg* corrected p-value ≤ 0.05 , two-
163 sided hypergeometric test) were taken into account. The rest of the settings were used as default. For
164 simplification, the leading term from each group is presented. The percentage of detected features over all
165 associated genes per group is also displayed under the column “% association” (Tables S2a-S2e).


166 For the disease association analysis the Open Targets platform was used. The hypergeometric distribution
167 and a scoring process based on evidence from 20 data sources (e.g. Uniprot, GWAS Catalog and PheWAS) was
168 used to allow prioritization of targets based on the strength of their association with a disease. The scoring
169 process generate a relevance p value representing the probability that the given list of targets are specific to a
170 disease. Only urological cancers with a relevance p-value ≤ 0.05 were selected.

172 **3. Results**

173 **3.1 Establishment of optimized protocol**


174 Initial experiments were performed to establish an efficient and simple protocol for protein extraction from
175 FFPE tissue. The tested methods were based on earlier studies [20–23] and experience in our laboratory from
176 the analysis of tissue material of limited amount [25,26], taking also into account compatibility with mass
177 spectrometry. The methods ~~specifically~~included the use of four different protein extraction buffers in
178 combination to different homogenization means (Table 1 and Figures S1a-S1b). In all cases, 3 sections of ~~archival~~
179 liver and kidney FFPE tissues (as per availability) were employed, to simulate realistic scenarios of clinical
180 available starting material ~~scenarios~~from clinical samples. The yield and quality of extracted proteins were

1
2
3
4 181 initially evaluated by SDS-PAGE analysis (Figure S1a). ~~Based on this, following which~~, application of Tris-HCl, SDS
5 182 and DTE (FASP buffer) in combination with bead homogenization, sonication and boiling, was selected for
6
7 183 further detailed evaluation by GeLC-MS analysis. An overview of the applied workflow for the optimization of
8
9 184 the protein extraction from FFPE tissues is illustrated in Figure 1.
10
11 185



186

187



188

189

190 **Figure 1. Overview of the applied workflow for the FFPE protein extraction optimization.** ~~Eight~~Seven protocols
191 were tested and evaluated for the protein extraction ~~efficiency-efficacy~~ from FFPE tissues.

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207


208

209


For further evaluation of the ~~efficacy~~ efficiency of the protocol, a side by side comparison of FFPE tissue with respective fresh frozen (FF) mouse kidney tissue material was also performed. Specifically, 4 FFPE replicates and 2 FF replicates using different sections of the same sample for each type were used. In our analysis, we used reasonably stringent criteria (detailed in ~~materials~~Materials and ~~methods~~Methods) in order to eliminate most of the false positive protein identifications (IDs). ~~Based on these criteria, which 14802,056~~ unique proteins ~~derived from a list of 10661 identified peptides~~ were in total detected. The full list of proteins is reported in

Table S3a. Among the proteins that were identified, 853 identifications were based on ≥ 2 peptides and 627 were single peptide identifications. The selected protocol yielded a similar number of protein identifications-IDs from both FF and FFPE tissue (FF IDs: 1,736-1214 in 2 samples, FFPE IDs: 1,437-1249 in 4 samples) (Table S3a) and it was also found to provide reproducible results both within and between the two different preservation methods/sample types: an overlap rate of about 63-7251-62% among the total IDs of the FFPE samples (n=4 replicates) and a 93-9680-86% among the total IDs in FF samples (n=2 replicates) were noted. In addition, for the common proteins identified in all samples of a group (FF: 1,216, FFPE: 530), a high overlap between the FF and FFPE samples was noted with 610-502 proteins detected in both types of samples (Figure 2A and Table S3b). Importantly, a strong positive correlation in the relative abundances of the common proteins detected in all the FFPE and FF samples was noted (Spearman's rank-order correlation was also positive and statistically significant ($r_s = 0.8460.819$, $p < 0.01$, 2-tailed) (Figure 2B and Table S3b). Proteins identified from FF and FFPE samples were also mapped using the Gene Ontology term mapper (<https://go.princeton.edu/cgi-bin/GOTermMapper>) for cellular compartments. The generic terms Cytoplasm, Membrane and Nucleus were used for simplification. As shown in Figure 3, the detected proteins are distributed between the three main cellular compartments in a very similar way for the FFPE and FF samples (Figure 3). The same applies when protein segregation by molecular function was investigated as shown in Figure S2.


A




B



216



217
 218 **Figure 2. Reproducibility and effectiveness of the optimized proteomics protocol shown in a side by side**
 219 **comparison of FFPE with respective FF tissues.** A. The Venn diagram shows that there is significant overlap
 220 (n=~~610~~502 common identifications) among the proteins identified in all samples per group (n=4 for FFPE; n=2
 221 for FF)-FFPE and FF samples. B. A strong positive correlation is noted between the relative abundances of the
 222 610502 common proteins identified in all FF and FFPE samples (Spearman's rho=~~0.846~~0.819).




225
 226 **Figure 3. Distribution of the total number of proteins identified in FF and FFPE tissues among the three main**
 227 **cellular compartments.** The percentages have been calculated against the total component hits.

230 3.2 Application in analysis of FFPE PCa tissue

1
2
3 231 The optimized protocol was then implemented in a preliminary study aiming to analyze archived clinical
4
5 232 prostate FFPE samples representing different risk categories. ~~Specifically, T~~the study ~~specifically~~involved the
6
7 233 analysis of 18 FFPE PCa tissue samples, representing GS=6, GS≥8 and respective adjacent benign regions.
8
9 234 Analysis by GeLC-MS/MS, in this case, provided a mean of approximately 700 proteins per sample, ~~apparently a~~
10
11 235 lower ~~number compared~~ to the ~~obtained~~ protein identifications ~~obtained during the protocol optimization~~ in
12
13 236 mouse FFPE tissues. ~~, This result is~~ likely attributed to differences in fixation and storage conditions (~~Lists the~~
14
15 237 ~~lists~~ of detected proteins ~~is-are~~ provided in Table S4a).

16
17 238 Five different comparisons were performed: GS≥8 cancer versus GS=6 cancer tissue, GS≥8 adjacent benign
18
19 239 versus GS=6 adjacent benign tissue, GS=6 cancer versus GS=6 adjacent benign tissue, GS≥8 cancer versus GS≥8
20
21 240 adjacent benign tissue, ~~and all analyzed cancer samples (GS=6 and GS≥8) cancer tissues~~ versus ~~all analyzed~~
22
23 241 ~~benign samples (GS=6 and GS≥8 adjacent benign tissues)~~. To graphically represent the proteomic changes
24
25 242 between the different groups of ~~tissuesamples~~, a volcano plot [$-\log_{10}(\text{P value})$ vs. $\log_2(\text{Fold-change})$] was
26
27 243 constructed for each one of the comparisons ~~groups~~ (Figure 4) ~~and the number of differentially expressed~~
28
29 244 ~~proteins per comparison is summarized in Table S4g~~. As ~~it is~~ shown in all plots, the population of the proteins
30
31 245 above and below the cut-offs is symmetrically distributed. Indicative ~~differentially expressed~~ proteins ~~changes~~
32
33 246 are shown in ~~tables-Tables 2 and 3, and~~ including proteins ~~involved in of the~~ ECM organization, chromosomal
34
35 247 and cytoskeletal proteins, proteins ~~that~~ implicated in translation and in ~~the processes of endocytosis and~~
36
37 248 ~~/exocytosis. These observations which~~ are ~~also~~ consistent with ~~already~~ published data ~~as shown in Tables (Table~~
38
39 249 ~~2, and Table 3)~~.



250

Figure 4. Volcano plot illustrates significantly differentially abundant proteins in the comparisons. A. All cancers (GS=6, GS≥8) cancer vs. all benign (GS=6, GS≥8 adjacent benign), B. GS≥8 cancer vs. GS=6 cancer, C. GS=6 cancer vs. GS=6 benign, D. GS≥8 cancer vs. GS≥8 benign and E. GS≥8 benign vs. GS=6 benign. The $-\log_{10}$ (Benjamini-Hochberg corrected p-value) is plotted against the \log_2 (fold change). The non-axial vertical lines denote ± 1.5 -fold change; Points points to the left of the left-most non-axial vertical line denote protein fold changes less than -1.5, while points to the right of the right-most non-axial vertical line denote protein fold changes greater than 1.5. The non-axial horizontal line denotes P-p-value =0.05 (Mann-Whitney), which is our significance threshold prior to logarithmic transformation; P and points above the non-axial horizontal line represent proteins with significantly differences differentia abundances (Mann-Whitney $p < 0.05$).

Table 2. Top 20 differentially expressed proteins showing the most significant abundance changes between GS=6 cancer and GS=6 adjacent benign counterparts, based on a ranking combining the protein abundance ratio and the p-value from the Mann-Whitney test ($\log_2(\text{Ratio}) * -\log_{10}(p\text{-value})$). Literature information for proteins that have been previously studied-reported in association to PCa are is also given.

Accession ID	Description	Gene Symbol	Ratio GS6 cancer Vs GS6 benign	M-W p-value GS6 cancer Vs GS6 benign	Reference *
Up-regulated in cancer					
P16104	Histone H2AX	H2AFX	100.049	0.011	
P63241	Eukaryotic translation initiation factor 5A-1	EIF5A	43.448	0.011	
P13647	Keratin, type II cytoskeletal 5 *	KRT5	25.641	0.011	[27,28]
P02511	Alpha-crystallin B chain *	CRYAB	20.504	0.021	[29,30]
P61158	Actin-related protein 3	ACTR3	20.334	0.046	
P54819	Adenylate kinase 2, mitochondrial	AK2	18.090	0.021	
O00148	ATP-dependent RNA helicase DDX39A	DDX39A	9.721	0.011	
P14550	Alcohol dehydrogenase [NADP(+)]	AKR1A1	7.290	0.021	
Q96E39	RNA binding motif protein, X-linked-like-1	RBMXL1	6.436	0.013	
P32969	60S ribosomal protein L9	RPL9	6.330	0.021	
Up-regulated in benign					
Q15149	Plectin *	PLEC	0.266	0.014	[31]
P01008	Antithrombin-III	SERPINC1	0.251	0.014	[32]
P61019	Ras-related protein Rab-2A	RAB2A	0.222	0.014	
P08133	Annexin A6	ANXA6	0.183	0.014	
P84243	Histone H3.3	H3F3A	0.180	0.014	
P15090	Fatty acid-binding protein, adipocyte *	FABP4	0.166	0.014	[33,34]
Q9Y6C2	EMILIN-1	EMILIN1	0.162	0.027	
P18206	Vinculin	VCL	0.155	0.014	[35,36]

P98160	Heparan sulfate proteoglycan core protein <u>1*</u>	HSPG2	0.136	0.05	[37,38]
P59665	Neutrophil defensin 1	DEFA1	0.069	0.014	[39]

¹The asterisk indicates an opposite expression trend compare to the finding in the current study or contradictory literature data
²* Literature information have has been retrieved from studies comparing PCa versus BPH and/or benign and/or normal in tissues or models by applying different methodological approaches (IHC, Western blot, mass spectrometry).





Table 3. Top 20 differentially expressed proteins ~~showing the most significant abundance changes~~ between GS \geq 8 cancer and GS \geq 8 adjacent benign ~~counterparts~~, based on a ranking combining the protein abundance ratio and the p-value from the Mann-Whitney test ($\log_2(\text{Ratio}) * -\log_{10}(\text{p-value})$). Literature information for proteins that have been previously reported in association to PCa studied are is also given.

Accession ID	Description	Gene Symbol	Ratio GS \geq 8 cancer Vs GS \geq 8 benign	M-W p-value GS \geq 8 cancer Vs GS \geq 8 benign	Reference <u>*</u>
Up-regulated in cancer					
Q13162	Peroxiredoxin-4	PRDX4	11.000	0.013	[6,40,41]
P08779	Keratin, type I cytoskeletal 16	KRT16	8.578	0.014	[42]
P02533	Keratin, type I cytoskeletal 14 <u>*</u>	KRT14	5.395	0.014	[43]
P21397	Amine oxidase [flavin-containing] A	MAOA	5.273	0.049	[44]
P05141	ADP/ATP translocase 2	SLC25A5	4.672	0.046	
P54819	Adenylate kinase 2, mitochondrial	AK2	4.637	0.05	
P31040	Succinate dehydrogenase flavoprotein	SDHA	4.204	0.049	[45]
Q9NVD7	Alpha-parvin	PARVA	3.708	0.049	[46]
Q9UHG3	Prenylcysteine oxidase 1	PCYOX1	3.662	0.049	
P13639	Elongation factor 2	EEF2	2.774	0.014	[47]
Up-regulated in benign					
Q6PCB0	von Willebrand factor A domain-protein 1	VWA1	0.489	0.014	
P60660	Myosin light polypeptide 6	MYL6	0.488	0.027	
P15088	Mast cell carboxypeptidase A	CPA3	0.355	0.05	
P00387	NADH-cytochrome b5 reductase 3	CYB5R3	0.287	0.05	
Q08257	Quinone oxidoreductase	CRYZ	0.275	0.027	[48,49]
O75368	SH3 domain-binding glutamic acid-rich-like	SH3BGRL	0.246	0.014	
O14558	Heat shock protein beta-6	HSPB6	0.223	0.05	
Q08380	Galectin-3-binding protein <u>*</u>	LGALS3BP	0.203	0.014	[50]
P08648	Integrin alpha-5 <u>*</u>	ITGA5	0.121	0.014	[51]

1
2
3
4 P30046 D-dopachrome decarboxylase DDT 0.081 0.021
5 279

6 280 ¹The asterisk indicates an opposite expression trend compare to the finding in the current study or contradictory literature data
7 281 ^{2*} Literature information ~~have~~ has been retrieved from studies comparing PCa versus BPH and/or benign and/or normal in tissues or
8 282 models by applying different methodological approaches (IHC, Western blot, mass spectrometry).
9 283

10 284
11
12 285 Significantly differentially expressed proteins were subjected to pathway classification, using the Reactome
13
14 286 database, to investigate the deregulated molecular pathways (Figure 5 and Tables S2a-S2e). To simplify the
15
16 287 analysis output, only the leading terms of each pathway are presented. Proteins significantly deregulated
17
18 288 between the more aggressive PCa GS \geq 8 and PCa ~~of~~ GS=6 ~~were~~ segregated into pathways involved in metabolism
19
20 289 and kinase signalling extracellular matrix interactions and organisation, protein phosphorylation and
21
22 290 gluconeogenesis, in line to existing literature [52,53] on aggressive forms of prostate cancer (Figure 5A). On the
23
24 291 other hand, when comparing the cancerous tissues with the adjacent benign counterpartstissues, in all cases,
25
26 292 the pathways that were enriched in the former, represented translation, peptide synthesis and protein
27
28 293 metabolism (Figure 5B, C, D), as expected [54,55].
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



295 **Figure 5. Enrichment pathway analysis of the proteins with significant differences between the different**
296 **comparing groups.** Only the leading terms of each pathway group are presented, based on significance which
297 is illustrated from the size of the bars. Green color illustrates the pathways that contain more than 50% of genes
298 ~~which~~ found up-regulated in case (always the first group in each graph title) versus control (always the second
299 group in graph title). ~~While the p~~Pathways containing more than 50% of genes up-regulated in control versus
300 case, are illustrated with red color. A. $GS \geq 8$ cancer vs. $GS = 6$ cancer, B. $GS = 6$ cancer vs. $GS = 6$ benign, C. $GS \geq 8$
301 cancer vs. $GS \geq 8$ benign and D. ~~all~~ $GS = 6$ and $GS > 8$ cancer vs. ~~all~~ $GS = 6$ and $GS > 8$ benigns.

303 To further evaluate our findings, the differentially expressed proteins from the comparison of cancer ($GS = 6$
304 and $GS \geq 8$) versus benign ($GS = 6$ and $GS \geq 8$) were analysed on the Open Targets Platform [56] which combines
305 evidence from various data sources, allowing target identification, ~~and~~ prioritisation, ~~as well as and~~ association
306 with diseases. The analysis demonstrated that out of the 180 significantly differentially expressed proteins found
307 in this comparison, 106 have been significantly (stat. test p-value ≤ 0.05) associated with prostate cancer
308 including prostate carcinoma and adenocarcinoma, and metastatic prostate cancer. Furthermore, out of these
309 106 PCa associations, 86 were also associated with other urological cancers (bladder, kidney and testicular
310 carcinoma) while 19 more proteins were found to be implicated only in other urological cancers and not in
311 prostate malignancies. The results of the disease association analysis are shown in detail in Table S5. The high
312 percentage of associations with PCa in this analysis supports the relevance of our proteomics results in the
313 context of PCa and the efficiency of the optimized protein extraction protocol used for FFPE samples.

315 4. Discussion

316 There are relatively few published proteomic analyses of FFPE prostate tissues [6] (summarized in Table
317 S6a). The majority of the studies focused on methodological approaches of extracting proteins from FFPE blocks
318 using either low resolution proteomics techniques or applying LC-MS/MS with extensive fractionation and
319 expensive labeling protocols [19–21,57–59]. ~~Specifically~~~~Characteristically~~, there are three proteomic reports
320 using an SDS-based extraction protocol combined with heating and LC-MS/MS as proteomic platform to
321 elucidate protein differences between FFPE PCa tissues and the adjacent counterparts. Using a case-control
322 study design, Dunne et al. [23] used LC-MS/MS to identify protein changes between 16 primary PCa cases of GS
323 6-10 and 16 adjacent benign areas, ~~in this study, resulting in~~ 242 protein IDs, in total. In a similar report, Iglesias
324 et al., using an SDS-based extraction buffer and LC-MS/MS with extensive fractionation of the samples, were
325 able to identify 649 differentially expressed proteins between 28 PCa samples (GS 6-9) and 8 adjacent
326 nonmalignant tissues [22]. Moreover, Turiak et al. used tissue microarrays TMAs from FFPE blocks, including 10
327 cases of PCa and 2 healthy prostate tissues, resulting in the identification of 500 proteins on average, from each
328 sample, using label-free quantitative LC-MS/MS analysis, also showing high grade of technical reproducibility

1
2
3 329 [8]. A cumulative table of the proteomic studies using FFPE tissues in the context of PCa and their main
4 characteristics is presented (Table S6a). A comparison of the differentially expressed proteins in the current
5 330 study with the significantly altered proteins reported by Iglesias-Gato et al. [22] (PCa GS 6-9 vs adjacent benign)
6 331 is presented in Table S6b, as it is the only study performing a similar comparison to ours (PCa GS=6 and GS≥8 vs
7 adjacent benign). In total, 107 proteins were differentially expressed in both studies, out of which, 83 follow the
8 332 same expression trend in cancer compared to adjacent benign.
9 333
10 334

11
12
13 335 Our overall goal for this study was to investigate whether differential protein expression analysis from
14 336 archival FFPE prostate cancer tissues with a simple, fast and label-free protocol using high resolution proteomics
15 337 is feasible. Following an initial method development phase evaluating ~~eight~~seven different protocols, compiling
16 338 information from the existing literature [19–21,57–59], use of an extraction buffer including 100mM Tris-HCl, 4
17 339 % SDS, 100mM DTE in combination with bead homogenization, sonication and boiling was selected.

18 340 This optimized buffer contained 4% SDS, higher than the ~~least~~-recommended concentration for such
19 341 analyses (2% SDS; [60]) and reported to effectively solubilize fixed proteins from FFPE tissues due to its dual
20 342 denaturing and detergent actions [15,61].- Increase in protein extraction efficacy was noted when this buffer
21 343 was combined with at least 60 °C heating. This is in line to several studies supporting a direct correlation
22 344 between the protein yield from FFPE specimens and applied temperature [18,59,62,63]. Specifically, it has been
23 345 suggested that heating may lead to protein unfolding, removal of covalent cross-links and hydrolysis of
24 346 methylene bridges [62–64] with optimal results obtained at 65°C [59]. Besides the temperature, the effect of
25 347 pH on the protein extraction efficacy has also been reported [16,59,62]. Several studies agree on the general
26 348 finding that incubation of FFPE sections in buffers with basic pH (~8.0) give higher yield, while extraction in
27 349 acidic or close to neutral pH (~7-7.5), generally provide a lower protein amount [16,59,62]. Our protocol, which
28 350 includes an extraction buffer with pH (~~~8.0~~), is also in line with these reports.

29 351 Several studies aim Targeting to evaluate if the FFPE tissues ~~form offer~~ a reliable alternative to ~~fresh frozen~~FF
30 352 samples, several studies have been performed by comparing the protein profiles between the two types of
31 353 samples [59,60,65–67]. Overlaps in protein identifications between the FFPE and FF samples are in general high,
32 354 ~~with rates~~-ranging between 75 and 92% [59,60,65–67]. Higher variability is noted in the number of identified
33 355 proteins per study: In some cases, clear superiority of the FF over the FFPE samples [15,65,68,69] was observed
34 356 , while others reported comparable results [70,71]. In one case, a higher number of protein identifications (by
35 357 about 30%) in FFPE samples compared to FF tissue was ~~observed reported~~ [72]. These results may largely reflect
36 358 differences among individual protocols but also the potential impact of the fixation protocols and storage
37 359 conditions, which ~~cannot generally not~~ be controlled, generally, when analyzing archival tissues. In our analysis,
38 360 the described protocol resulted in the detection of about ~~1000~~950 proteins on average, in FFPE samples, which

1
2
3 361 ~~is still lower to the respective FF output (about 1,500 proteins on average, per sample). However, the two types~~
4 ~~of samples had~~ with high overlap rates ~~in their protein IDs (95% of the FFPE and 41% of the FF protein IDs were~~
5 ~~common)~~ and significant correlation ($r_s = 0.8460.819$, $p < 0.01$) in the relative protein abundances, ~~when the~~
6 ~~FFPE tissues were compared with the respective FF tissues.~~ Additionally, GO analysis ~~supported~~ showed that
7 364 similar percentages of membrane proteins isolated from FFPE and FF tissues were detected. This further
8 365 ~~suggests~~ supports the efficacy of the applied protocol and its potential usefulness in the study of ~~tumor~~ tumor-
9 366 relevant signaling pathways.

10 367
11 368 In the context of this study, the optimized protocol was implemented in a proof of concept analysis of 18
12 369 FFPE PCa tissue samples, representing GS=6, GS≥8 and respective adjacent benign regions. Of the detected
13 370 proteins, the vast ~~number~~ majority of the high abundance identifications were cytoskeletal and ribosomal
14 371 proteins, as well as nuclear histones, as expected [73]. Comparisons of the different groups highlighted many
15 372 expected protein changes in cancer, based on the current literature. These include as examples, Peroxiredoxins
16 373 3 and 4 ~~(PRDX3 and PRDX4)~~, Methylcrotonoyl - CoA carboxylase beta chain ~~(MCCC2)~~, Vinculin ~~(VCL)~~ and
17 374 Prohibitin ~~(PHB)~~, previously validated in more than one study as deregulated in PCa compared to adjacent
18 375 benign tissues, ~~similarly~~ found ~~to~~ differentially expressed ~~and~~ with same trends of expression in the studied
19 376 cancer cases versus adjacent controls [6]. Interestingly, in the comparisons GS≥8 versus GS=6 cancerous tissues,
20 377 GS≥8 adjacent benign tissues versus GS=6 adjacent benign tissues, GS≥8 cancerous tissues versus GS≥8 adjacent
21 378 benign tissues, albeit non-statistically significant in the two latter cases, PSA was found down regulated by at
22 379 least 0.2-fold, in GS≥8 groups, ~~in the aforementioned comparisons~~. This finding is also supported by a targeted
23 380 proteomic study utilizing Selected Reaction Monitoring (SRM) in tissue samples where it was shown that PSA
24 381 levels decreased in localized PCa (GS=7) and in metastatic PCa tumors when compared to benign tissues [74].
25 382 Multiple additional proteins (in total 25 out 63 [75]) earlier reported to differ in cancer versus benign [75] were
26 383 also detected as differentially expressed in our respective comparison. Out of these 25 proteins, 21 exhibit the
27 384 same expression trend in our data and previous reports [75]; these include Keratin, type II cytoskeletal 8,
28 385 Peroxiredoxin-4, Growth/differentiation factor 15, Eukaryotic initiation factor 4A-III, Metalloproteinase inhibitor
29 386 1, that and others were specifically found also to agree in the expression trend in similar comparison groups as
30 387 in our study (Table S6S7).

31 388 The relevance of the proteomics ~~output result observed at the individual protein level~~ was also observed
32 389 when investigating biological processes reflected by the observed protein changes, with Neutrophil
33 390 degranulation [76], Rho GTPase signaling [77], mRNA metabolic processes [54], glycolysis/glyconeogenesis
34 391 pathway [54] and mitogen-activated protein kinases ~~(MAPK)~~ signaling [78] predicted to be changing in GS≥8 vs
35 392 GS=6 as earlier reported. Similarly, significantly deregulated proteins in cancer versus benign segregated into

1
2
3 393 pathways relevant to cancer molecular pathology such as ~~or and~~ protein translation [55], ECM organization [79]
4 and mRNA splicing [80]. ~~in cancer versus benign, as earlier reported.~~ Collectively, these results support the
5 reliability of the established procedure and further applicability to extract valuable information at the protein
6 395
7 level, forming the basis for its further use in large scale PCa –related molecular studies.
8 396

9
10 397 Along the same lines, since androgen receptor (AR) signaling is known to play an important role in the
11 pathogenesis of PCa [81,82], we also investigated the differentially expressed proteins in our comparisons in
12 regards to their association with the AR pathway (based on PathCards [83,84]). Interestingly, AR-linked proteins
13 were included, namely, Filamin-A (GS \geq 8 cancer vs. GS=6 cancer; GS=6 cancer vs. GS=6 benign); GTP-binding
14 nuclear protein Ran A (GS \geq 8 cancer vs. GS=6 cancer; GS=6 cancer vs. GS=6 benign); Destrin (GS \geq 8 cancer vs.
15 GS=6 cancer); Caveolin-1 (GS \geq 8 cancer vs. GS=6 cancer); Prostate-specific antigen (GS \geq 8 cancer vs. GS=6 cancer);
16 and Receptor of activated protein C kinase 1 (GS=6, GS \geq 8 cancer vs. GS=6, GS \geq 8 benign; GS=6 cancer vs. GS=6
17 benign). Additional proteins from our datasets, that are linked to the pathway but did not pass our criteria for
18 differential expression, include Catenin beta-1; Cell division control protein 42 homolog; Calreticulin;
19 Protein/nucleic acid deglycase DJ-1; and Peroxiredoxin-1. These findings further enhance the validity of our
20 proteomic results but the analysis of a bigger cohort is needed to draw solid conclusions with respect to the
21 biological relevance of these results.
22 404
23 405
24 406
25 407
26 408

27 409 It should be noted that the analyzed sections contain stroma elements and no specific enrichment for
28 epithelial components was made in the context of this pilot study. Upon comparison with an earlier proteomic
29 analysis of normal and diseased stroma isolated from PCa patients [85], an overlap of 30-40 proteins from the
30 earlier described differentially expressed proteins with the total protein identification from each of the
31 comparisons in our study may be seen, which might reflect the stroma influence in the results.
32 410
33 411
34 412
35 413
36 414

415 5. Conclusions

416 From a methodological standpoint, the protocol presented here combining different aspects of earlier
417 described protocols, is simple and fast, applicable to limited amounts of clinical samples (as expected in the
418 cases of small pieces of tissue biopsies), yielding comprehensive datasets that permit further investigation and
419 knowledge extraction. With no doubt, due to the expected variability associated with differences in fixation and
420 storage conditions, future studies should include the analysis of large numbers of well characterized FFPE
421 samples with advanced LC/MS-MS approaches, targeting to reliably reveal protein changes associated with PCa
422 phenotypes and progression.
423

424 SUPPORTING INFORMATION:

1
2
3 425 Figure S1. Protocol optimization for protein extraction from the FFPE blocks. Impact of buffer and
4
5 426 homogenization means on extracted proteins as defined by SDS-PAGE.

6
7 427 Figure S2. GO Molecular functional comparative analysis between FF and FFPE tissues. The genes corresponding
8
9 428 to the total number of proteins ~~that totally~~ identified in FF and FFPE samples were mapped using the Gene
10
11 429 Ontology term mapper (<https://go.princeton.edu/cgi-bin/GOTermMapper>) for molecular functions.
12
13 430 ~~Importantly~~As shown, the genes are distributed between the molecular functions in a very similar way in the
14
15 431 FFPE and the FF samples.

16
17 432 Table S1. Clinical characteristics of the patient cohort. This study comprised 10 patients with histologically
18
19 433 confirmed PCa in radical prostatectomy. Five patients had Gleason score 6 (3+3) and five patients has Gleason
20
21 434 scores 8 (4+4) and 9 (4+5 or 5+4). Here, specimens of the primary tumors ~~that were investigated were~~ stored as
22
23 435 FFPE blocks ~~were analyzed~~.

24
25 436 Table S2. ~~Enrichment analysis for Reactome pathways for the comparisons (a) GS \geq 8 cancer vs. GS \geq 8 benign, (b)~~
26
27 437 ~~GS=6 cancer vs. GS=6 benign, (c) Cancer (GS=6, GS \geq 8) vs. Benign (GS=6, GS \geq 8), (d) GS \geq 8 cancer vs. GS=6 cancer,~~
28
29 438 ~~(e) GS \geq 8 benign vs. GS=6 benign. Only the significantly differentially expressed proteins were used as input and~~
30
31 439 ~~only the leading terms based on significance are presented.~~Enrichment analysis for Reactome pathways for the
32
33 440 comparisons ~~GS \geq 8 cancer vs. GS \geq 8 benign (Table S2a), GS=6 cancer vs. GS=6 benign (Table S2b), Cancer~~
34
35 441 ~~(GS=6,GS \geq 8) vs. Benign (GS=6,GS \geq 8) (Table S2c), GS \geq 8 cancer vs. GS=6 cancer (Table S2d), GS \geq 8 benign vs. GS=6~~
36
37 442 ~~benign (Table S2e). Only the significantly differentially expressed proteins were input and only the leading terms~~
38
39 443 ~~based on significance are presented.~~

40
41 444 Table S3. ~~All proteins detected per sample as well as a Spearman's correlation analysis between FFPE and FF~~
42
43 445 ~~mouse kidney tissues are shown (a) All proteins detected per sample are listed below. The raw area values are~~
44
45 446 ~~given. Zeros indicate the missing values, the proteins that have not been detected (b) Correlation analysis~~
46
47 447 ~~between FFPE and FF mouse kidney tissues. The numbers given refer to proteins which were present in ALL the~~
48
49 448 ~~replicates per group. Spearman's correlation values have been calculated per wise for the samples individually~~
50
51 449 ~~but also for the average values.~~All proteins detected per sample as well as a Spearman's correlation analysis
52
53 450 ~~between FFPE and FF mouse kidney tissues are shown.~~

54
55 451 Table S4. ~~a) All proteins detected per sample in the clinical FFPE tissues are shown. Differential expression~~
56
57 452 ~~analysis for the comparisons (b) GS \geq 8 cancer vs. GS=6 cancer, (c) GS \geq 8 benign vs. GS=6 benign, (d) GS=6 cancer~~
58
59 453 ~~vs. GS=6 benign, (e) GS \geq 8 cancer vs. GS \geq 8 benign, (f) Cancer (GS=6, GS \geq 8) vs. Benign (GS=6, GS \geq 8) are given~~
60
454 ~~indicating the proteins below the threshold for significance (p-value \leq 0.05) and with an abundance ratio \geq 1.5~~
455 ~~with green color and proteins with p-value \leq 0.05 and abundance ratio \leq 0.67 with red color. (g) Summary of the~~
456 ~~significantly deregulated proteins per comparison.~~All proteins detected per sample in the clinical FFPE tissues

are shown. Differential expression analysis for all the comparison groups are given as well indicating the proteins below the threshold for significance ($p\text{-val} \leq 0.05$) and with an abundance ratio ≥ 1.5 with green color and proteins with $p\text{-val} \leq 0.05$ and abundance ratio ≤ 0.67 with red color.

Table S5. Results from the disease association of the significantly differentially expressed proteins in the comparison GS \geq 8, GS=6 of all cancers (case) vs GS \geq 8, GS=6 all adjacent benign (control) using the Open Targets Platform.

Table S6 (a) An overview of proteomics studies performed in FFPE tissues in the context of prostate cancer. (b) Comparison of the findings in the current study with the study by Iglesias-Gato et al. 2015 (PMID: 26651926) in the same comparison between Tumor (n=28) and adjacent non-malignant prostate tissue (n=8). Multiple proteins (in total 107 out of 649), earlier reported to differ in cancer versus benign, were also detected as differentially expressed in our respective comparison GS \geq 8, GS=6 cancer (case) vs adjacent benign GS \geq 8, GS=6 (control). Proteins that exhibit the same expression trend are highlighted.

Table S76. Comparison of the findings in the current study with the literature (review, PMID: 29939814). Multiple proteins (in total 25 out of 63), earlier reported to differ in cancer versus benign, were also detected as differentially expressed in our respective comparison GS \geq 8, GS=6 cancer (case) vs adjacent benign GS \geq 8, GS=6 (control). Proteins that exhibit the same expression trend in similar comparisons in our data and previous reports are highlighted. Comparison of the findings in the current study with the literature (Review 2017). Multiple proteins (in total 25 out 63) earlier reported to differ in cancer versus benign were also detected as differentially expressed in our respective comparison GS8, GS6 cancer(case) Vs adjacent benignGS \geq 8, GS=6 (control); Proteins that exhibit the same expression trend and in similar comparison groups in our data and previous reports are highlighted.

478

479 Funding

480 This work was supported by Translational Research Network for Prostate Cancer (721746 - TransPot - H2020 -
481 MSCA - ITN - 2016) 721746.

482

483 Conflict of interest

484 All authors declare no competing financial interest.

485

486 References

487

- 1
2
3 488 [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN
4 489 estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*
5 490 2018;68:394–424. doi:10.3322/caac.21492.
- 7 491 [2] Romero Otero J, Garcia Gomez B, Campos Juanatey F, Touijer KA. Prostate cancer biomarkers: an
8 492 update. *Urol Oncol* 2014;32:252–260. doi:10.1016/j.urolonc.2013.09.017.
- 10 493 [3] Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer
12 494 biomarkers. *Sci Transl Med* 2012;4:127rv3. doi:10.1126/scitranslmed.3003180.
- 14 495 [4] Alford AV, Brito JM, Yadav KK, Yadav SS, Tewari AK, Renzulli J. The use of biomarkers in prostate cancer
15 496 screening and treatment. *Rev Urol* 2017;19:221–234. doi:10.3909/riu0772.
- 17 497 [5] Frank S, Nelson P, Vasioukhin V. Recent advances in prostate cancer research: large-scale genomic
18 498 analyses reveal novel driver mutations and DNA repair defects. [version 1; peer review: 2 approved].
19 499 *F1000Res* 2018;7. doi:10.12688/f1000research.14499.1.
- 21 500 [6] Mantsiou A, Vlahou A, Zoidakis J. Tissue proteomics studies in the investigation of prostate cancer.
22 501 *Expert Rev Proteomics* 2018;15:593–611. doi:10.1080/14789450.2018.1491796.
- 24 502 [7] Müller A-K, Föll M, Heckelmann B, Kiefer S, Werner M, Schilling O, et al. Proteomic characterization of
25 503 prostate cancer to distinguish nonmetastasizing and metastasizing primary tumors and lymph node
26 504 metastases. *Neoplasia* 2018;20:140–151. doi:10.1016/j.neo.2017.10.009.
- 28 505 [8] Turiák L, Ozohanics O, Tóth G, Ács A, Révész Á, Vékey K, et al. High sensitivity proteomics of prostate
29 506 cancer tissue microarrays to discriminate between healthy and cancerous tissue. *J Proteomics*
31 507 2019;197:82–91. doi:10.1016/j.jprot.2018.11.009.
- 33 508 [9] Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, et al. The proteogenomic landscape of
34 509 curable prostate cancer. *Cancer Cell* 2019;35:414–427.e6. doi:10.1016/j.ccell.2019.02.005.
- 36 510 [10] Latonen L, Afyounian E, Jylhä A, Nättinen J, Aapola U, Annala M, et al. Integrative proteomics in
37 511 prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease
38 512 progression. *Nat Commun* 2018;9:1176. doi:10.1038/s41467-018-03573-6.
- 40 513 [11] Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Mining the archival formalin-fixed paraffin-embedded
41 514 tissue proteome: opportunities and challenges. *Mol Biosyst* 2008;4:712–720. doi:10.1039/b800098k.
- 43 515 [12] Knezevic D, Goddard AD, Natraj N, Cherbavaz DB, Clark-Langone KM, Snable J, et al. Analytical
44 516 validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate
45 517 needle biopsies. *BMC Genomics* 2013;14:690. doi:10.1186/1471-2164-14-690.
- 47 518 [13] Mason JT, O’Leary TJ. Effects of formaldehyde fixation on protein secondary structure: a calorimetric
48 519 and infrared spectroscopic investigation. *J Histochem Cytochem* 1991;39:225–229.
50 520 doi:10.1177/39.2.1987266.
- 52 521 [14] Matsuda KM, Chung J-Y, Hewitt SM. Histo-proteomic profiling of formalin-fixed, paraffin-embedded
53 522 tissue. *Expert Rev Proteomics* 2010;7:227–237. doi:10.1586/epr.09.106.

- 1
2
3 523 [15] Jiang X, Jiang X, Feng S, Tian R, Ye M, Zou H. Development of efficient protein extraction methods for
4 524 shotgun proteome analysis of formalin-fixed tissues. *J Proteome Res* 2007;6:1038–1047.
5 525 doi:10.1021/pr0605318.
- 7 526 [16] Azimzadeh O, Barjaktarovic Z, Aubele M, Calzada-Wack J, Sarioglu H, Atkinson MJ, et al. Formalin-fixed
8 527 paraffin-embedded (FFPE) proteome analysis using gel-free and gel-based proteomics. *J Proteome Res*
9 528 2010;9:4710–4720. doi:10.1021/pr1004168.
- 11 529 [17] Magdeldin S, Yamamoto T. Toward deciphering proteomes of formalin-fixed paraffin-embedded (FFPE)
12 530 tissues. *Proteomics* 2012;12:1045–1058. doi:10.1002/pmic.201100550.
- 15 531 [18] Ikeda K, Monden T, Kanoh T, Tsujie M, Izawa H, Haba A, et al. Extraction and Analysis of Diagnostically
16 532 Useful Proteins from Formalin-fixed, Paraffin-embedded Tissue Sections. *Journal of Histochemistry &*
17 533 *Cytochemistry* 1998;46:397–403. doi:10.1177/002215549804600314.
- 19 534 [19] Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, et al. Proteomic analysis of
20 535 formalin-fixed prostate cancer tissue. *Mol Cell Proteomics* 2005;4:1741–1753.
21 536 doi:10.1074/mcp.M500102-MCP200.
- 23 537 [20] Pallua JD, Schaefer G, Seifarth C, Becker M, Meding S, Rauser S, et al. MALDI-MS tissue imaging
24 538 identification of biliverdin reductase B overexpression in prostate cancer. *J Proteomics* 2013;91:500–
25 539 514. doi:10.1016/j.jprot.2013.08.003.
- 28 540 [21] Davalieva K, Kiprijanovska S, Polenakovic M. Assessment of the 2-d gel-based proteomics application of
29 541 clinically archived formalin-fixed paraffin embedded tissues. *Protein J* 2014;33:135–142.
30 542 doi:10.1007/s10930-014-9545-2.
- 32 543 [22] Iglesias-Gato D, Wikström P, Tyanova S, Lavallee C, Thysell E, Carlsson J, et al. The proteome of primary
33 544 prostate cancer. *Eur Urol* 2016;69:942–952. doi:10.1016/j.eururo.2015.10.053.
- 35 545 [23] Dunne JC, Lamb DS, Delahunt B, Murray J, Bethwaite P, Ferguson P, et al. Proteins from formalin-fixed
36 546 paraffin-embedded prostate cancer sections that predict the risk of metastatic disease. *Clin Proteomics*
37 547 2015;12:24. doi:10.1186/s12014-015-9096-3.
- 39 548 [24] Makridakis M, Vlahou A. GeLC-MS: A Sample Preparation Method for Proteomics Analysis of Minimal
40 549 Amount of Tissue. *Methods Mol Biol* 2018;1788:165–175. doi:10.1007/7651_2017_76.
- 42 550 [25] Mokou M, Klein J, Makridakis M, Bitsika V, Bascands J-L, Saulnier-Blache JS, et al. Proteomics based
43 551 identification of KDM5 histone demethylases associated with cardiovascular disease. *EBioMedicine*
44 552 2019;41:91–104. doi:10.1016/j.ebiom.2019.02.040.
- 46 553 [26] Schanstra JP, Luong TTD, Makridakis M, Van Linthout S, Lygirou V, Latosinska A, et al. Systems biology
47 554 identifies cytosolic PLA2 as a target in vascular calcification treatment. *JCI Insight* 2019.
- 49 555 [27] Korshak OV, Sushilova EN, Voskresenskii MA, Grozov RV, Komyakov BK, Zarytskey AY, et al. [Basal-
50 556 luminal epithelial cell differentiation in prostate cancer is associated with epithelial-mesenchymal
51 557 transition and epithelium migration in the mesenchyme]. *Urologiia* 2016:85–91.


- 1
2
3 558 [28] Amaro A, Esposito AI, Gallina A, Nees M, Angelini G, Albin A, et al. Validation of proposed prostate
4 559 cancer biomarkers with gene expression data: a long road to travel. *Cancer Metastasis Rev*
5 560 2014;33:657–671. doi:10.1007/s10555-013-9470-4.
- 7 561 [29] Altintas DM, Allioli N, Decaussin M, de Bernard S, Ruffion A, Samarut J, et al. Differentially expressed
8 562 androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate
9 563 cancer. *PLoS One* 2013;8:e66278. doi:10.1371/journal.pone.0066278.
- 11 564 [30] Valcarcel-Jimenez L, Macchia A, Martín-Martín N, Cortazar AR, Schaub-Clerigué A, Pujana-Vaquerizo M,
12 565 et al. Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of
13 566 MITF in prostate cancer. *Cell Death Dis* 2018;9:1041. doi:10.1038/s41419-018-1096-6.
- 16 567 [31] Burch TC, Watson MT, Nyalwidhe JO. Variable metastatic potentials correlate with differential plectin
17 568 and vimentin expression in syngeneic androgen independent prostate cancer cells. *PLoS One*
18 569 2013;8:e65005. doi:10.1371/journal.pone.0065005.
- 20 570 [32] Hong SK, Ko DW, Park J, Kim IS, Doo SH, Yoon CY, et al. Alteration of Antithrombin III and D-dimer Levels
21 571 in Clinically Localized Prostate Cancer. *Korean J Urol* 2010;51:25–29. doi:10.4111/kju.2010.51.1.25.
- 23 572 [33] Wang Y, Guo W, Xu H, Zhu X, Yu T, Jiang Z, et al. An extensive study of the mechanism of prostate
24 573 cancer metastasis. *Neoplasma* 2018;65:253–261. doi:10.4149/neo_2018_161217N648.
- 26 574 [34] Elix C, Pal SK, Jones JO. The role of peroxisome proliferator-activated receptor gamma in prostate
27 575 cancer. *Asian J Androl* 2018;20:238–243. doi:10.4103/aja.aja_15_17.
- 29 576 [35] Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng NYW, et al. A transcriptional repressor co-regulatory
30 577 network governing androgen response in prostate cancers. *EMBO J* 2012;31:2810–2823.
31 578 doi:10.1038/emboj.2012.112.
- 34 579 [36] Geisler C, Gaisa NT, Pfister D, Fuessel S, Kristiansen G, Braunschweig T, et al. Identification and
35 580 validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and
36 581 MS. *Biomed Res Int* 2015;2015:454256. doi:10.1155/2015/454256.
- 38 582 [37] Suhovskih AV, Mostovich LA, Kunin IS, Boboev MM, Nepomnyashchikh GI, Aidagulova SV, et al.
39 583 Proteoglycan expression in normal human prostate tissue and prostate cancer. *ISRN Oncol*
40 584 2013;2013:680136. doi:10.1155/2013/680136.
- 42 585 [38] Tyutyunnykova A, Telegeev G, Dubrovskaya A. The controversial role of phospholipase C epsilon (PLCε) in
43 586 cancer development and progression. *J Cancer* 2017;8:716–729. doi:10.7150/jca.17779.
- 45 587 [39] Shapiro E, Huang H, Ruoff R, Lee P, Tanese N, Logan SK. The heterochromatin protein 1 family is
46 588 regulated in prostate development and cancer. *J Urol* 2008;179:2435–2439.
47 589 doi:10.1016/j.juro.2008.01.091.
- 50 590 [40] Basu A, Banerjee H, Rojas H, Martinez SR, Roy S, Jia Z, et al. Differential expression of peroxiredoxins in
51 591 prostate cancer: consistent upregulation of PRDX3 and PRDX4. *Prostate* 2011;71:755–765.
52 592 doi:10.1002/pros.21292.
- 53
54
55
56
57
58
59
60

- 1
2
3 593 [41] Tiedemann K, Sadvakassova G, Mikolajewicz N, Juhas M, Sabirova Z, Tabariès S, et al. Exosomal Release
4 594 of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis. *Transl Oncol* 2019;12:462–474.
5 595 doi:10.1016/j.tranon.2018.11.014.
6
7 596 [42] Rose A, Xu Y, Chen Z, Fan Z, Stamey TA, McNeal JE, et al. Comparative gene and protein expression in
8 597 primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer. *Cancer Lett*
9 598 2005;227:213–222. doi:10.1016/j.canlet.2005.01.037.
10
11 599 [43] van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell
12 600 keratins in human prostate cancer metastases and cell lines. *J Pathol* 2001;195:563–570.
13 601 doi:10.1002/path.993.
14
15 602 [44] Shih JC. Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
16 603 *J Neural Transm* 2018;125:1553–1566. doi:10.1007/s00702-018-1927-8.
17
18 604 [45] Feichtinger RG, Schäfer G, Seifarth C, Mayr JA, Kofler B, Klocker H. Reduced Levels of ATP Synthase
19 605 Subunit ATP5F1A Correlate with Earlier-Onset Prostate Cancer. *Oxid Med Cell Longev*
20 606 2018;2018:1347174. doi:10.1155/2018/1347174.
21
22 607 [46] Orr B, Riddick ACP, Stewart GD, Anderson RA, Franco OE, Hayward SW, et al. Identification of stromally
23 608 expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts
24 609 and fetal prostate. *Oncogene* 2012;31:1130–1142. doi:10.1038/onc.2011.312.
25
26 610 [47] Zhang X, Hu L, Du M, Wei X, Zhang J, Hui Y, et al. Eukaryotic elongation factor 2 (eef2) is a potential
27 611 biomarker of prostate cancer. *Pathol Oncol Res* 2018;24:885–890. doi:10.1007/s12253-017-0302-7.
28
29 612 [48] Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA. beta-Lapachone-induced
30 613 apoptosis in human prostate cancer cells: involvement of NQO1/xip3. *Exp Cell Res* 2001;267:95–106.
31 614 doi:10.1006/excr.2001.5234.
32
33 615 [49] Kumi-Diaka J, Saddler-Shawnette S, Aller A, Brown J. Potential mechanism of phytochemical-induced
34 616 apoptosis in human prostate adenocarcinoma cells: Therapeutic synergy in genistein and beta-
35 617 lapachone combination treatment. *Cancer Cell Int* 2004;4:5. doi:10.1186/1475-2867-4-5.
36
37 618 [50] Heger Z, Michalek P, Guran R, Cernei N, Duskova K, Vesely S, et al. Differences in urinary proteins
38 619 related to surgical ' ' margin status after radical prostatectomy. *Oncol Rep* 2015;34:3247–3255.
39 620 doi:10.3892/or.2015.4322.
40
41 621 [51] Feng J, Huang C, Diao X, Fan M, Wang P, Xiao Y, et al. Screening biomarkers of prostate cancer by
42 622 integrating microRNA and mRNA microarrays. *Genet Test Mol Biomarkers* 2013;17:807–813.
43 623 doi:10.1089/gtmb.2013.0226.
44
45 624 [52] Miller D, Ingersoll M, Lin M-F. ErbB-2 signaling in advanced prostate cancer progression and potential
46 625 therapy. *Endocr Relat Cancer* 2019;26:R195–R209. doi:10.1530/ERC-19-0009.
47
48 626 [53] Srihari S, Kwong R, Tran K, Simpson R, Tattam P, Smith E. Metabolic deregulation in prostate cancer.
49 627 *Mol Omics* 2018;14:320–329. doi:10.1039/c8mo00170g.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 628 [54] Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, et al. The role of tumor metabolism as a
4 629 driver of prostate cancer progression and lethal disease: results from a nested case-control study.
5 630 *Cancer Metab* 2016;4:22. doi:10.1186/s40170-016-0161-9.
- 6
7 631 [55] Ramamurthy VP, Ramalingam S, Kwegyir-Afful AK, Hussain A, Njar VCO. Targeting of protein translation
8 632 as a new treatment paradigm for prostate cancer. *Curr Opin Oncol* 2017.
9 633 doi:10.1097/CCO.0000000000000367.
- 10
11 634 [56] Carvalho-Silva D, Pierleoni A, Pignatelli M, Ong C, Fumis L, Karamanis N, et al. Open Targets Platform:
12 635 new developments and updates two years on. *Nucleic Acids Res* 2019;47:D1056–D1065.
13 636 doi:10.1093/nar/gky1133.
- 14
15 637 [57] Chu W-S, Liang Q, Liu J, Wei MQ, Winters M, Liotta L, et al. A nondestructive molecule extraction
16 638 method allowing morphological and molecular analyses using a single tissue section. *Lab Invest*
17 639 2005;85:1416–1428. doi:10.1038/labinvest.3700337.
- 18
19 640 [58] Hwang SI, Thumar J, Lundgren DH, Rezaul K, Mayya V, Wu L, et al. Direct cancer tissue proteomics: a
20 641 method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival
21 642 tissues. *Oncogene* 2007;26:65–76. doi:10.1038/sj.onc.1209755.
- 22
23 643 [59] Chung J-Y, Lee S-J, Kris Y, Braunschweig T, Traicoff JL, Hewitt SM. A well-based reverse-phase protein
24 644 array applicable to extracts from formalin-fixed paraffin-embedded tissue. *Proteomics Clin Appl*
25 645 2008;2:1539–1547. doi:10.1002/prca.200800005.
- 26
27 646 [60] Shi S-R, Liu C, Balgley BM, Lee C, Taylor CR. Protein extraction from formalin-fixed, paraffin-embedded
28 647 tissue sections: quality evaluation by mass spectrometry. *J Histochem Cytochem* 2006;54:739–743.
29 648 doi:10.1369/jhc.5B6851.2006.
- 30
31 649 [61] Ha GH, Lee SU, Kang DG, Ha N-Y, Kim SH, Kim J, et al. Proteome analysis of human stomach tissue:
32 650 separation of soluble proteins by two-dimensional polyacrylamide gel electrophoresis and identification
33 651 by mass spectrometry. *Electrophoresis* 2002;23:2513–2524. doi:10.1002/1522-
34 652 2683(200208)23:15<2513::AID-ELPS2513>3.0.CO;2-W.
- 35
36 653 [62] Yamashita S. Heat-induced antigen retrieval: mechanisms and application to histochemistry. *Prog*
37 654 *Histochem Cytochem* 2007;41:141–200. doi:10.1016/j.proghi.2006.09.001.
- 38
39 655 [63] Rait VK, Xu L, O’Leary TJ, Mason JT. Modeling formalin fixation and antigen retrieval with bovine
40 656 pancreatic RNase A II. Interrelationship of cross-linking, immunoreactivity, and heat treatment. *Lab*
41 657 *Invest* 2004;84:300–306. doi:10.1038/labinvest.3700041.
- 42
43 658 [64] Addis MF, Tanca A, Pagnozzi D, Crobu S, Fanciulli G, Cossu-Rocca P, et al. Generation of high-quality
44 659 protein extracts from formalin-fixed, paraffin-embedded tissues. *Proteomics* 2009;9:3815–3823.
45 660 doi:10.1002/pmic.200800971.
- 46
47 661 [65] Sprung RW, Brock JWC, Tanksley JP, Li M, Washington MK, Slebos RJC, et al. Equivalence of protein
48 662 inventories obtained from formalin-fixed paraffin-embedded and frozen tissue in multidimensional
49 663 liquid chromatography-tandem mass spectrometry shotgun proteomic analysis. *Mol Cell Proteomics*
50 664 2009;8:1988–1998. doi:10.1074/mcp.M800518-MCP200.

- 1
2
3 665 [66] Scicchitano MS, Dalmas DA, Boyce RW, Thomas HC, Frazier KS. Protein extraction of formalin-fixed,
4 666 paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry. *J Histochem*
5 667 *Cytochem* 2009;57:849–860. doi:10.1369/jhc.2009.953497.
- 7 668 [67] Guo T, Wang W, Rudnick PA, Song T, Li J, Zhuang Z, et al. Proteome analysis of microdissected formalin-
8 669 fixed and paraffin-embedded tissue specimens. *J Histochem Cytochem* 2007;55:763–772.
9 670 doi:10.1369/jhc.7A7177.2007.
- 11 671 [68] Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Development and validation of a novel protein extraction
12 672 methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using
13 673 western blotting. *J Pathol* 2009;217:497–506. doi:10.1002/path.2504.
- 16 674 [69] Gräntzdörffer I, Yumlu S, Gioeva Z, von Wasielewski R, Ebert MPA, Röcken C. Comparison of different
17 675 tissue sampling methods for protein extraction from formalin-fixed and paraffin-embedded tissue
18 676 specimens. *Exp Mol Pathol* 2010;88:190–196. doi:10.1016/j.yexmp.2009.09.009.
- 20 677 [70] Hood BL, Conrads TP, Veenstra TD. Mass spectrometric analysis of formalin-fixed paraffin-embedded
21 678 tissue: unlocking the proteome within. *Proteomics* 2006;6:4106–4114. doi:10.1002/pmic.200600016.
- 23 679 [71] Becker KF, Schott C, Hipp S, Metzger V, Porschewski P, Beck R, et al. Quantitative protein analysis from
24 680 formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis.
25 681 *J Pathol* 2007;211:370–378. doi:10.1002/path.2107.
- 27 682 [72] Palmer-Toy DE, Krastins B, Sarracino DA, Nadol JB, Merchant SN. Efficient method for the proteomic
28 683 analysis of fixed and embedded tissues. *J Proteome Res* 2005;4:2404–2411. doi:10.1021/pr050208p.
- 30 684 [73] Wang D, Eraslan B, Wieland T, Hallström B, Hopf T, Zolg DP, et al. A deep proteome and transcriptome
31 685 abundance atlas of 29 healthy human tissues. *Mol Syst Biol* 2019;15:e8503.
32 686 doi:10.15252/msb.20188503.
- 35 687 [74] Yocum AK, Khan AP, Zhao R, Chinnaiyan AM. Development of selected reaction monitoring-MS
36 688 methodology to measure peptide biomarkers in prostate cancer. *Proteomics* 2010;10:3506–3514.
37 689 doi:10.1002/pmic.201000023.
- 39 690 [75] Tanase CP, Codrici E, Popescu ID, Mihai S, Enciu A-M, Necula LG, et al. Prostate cancer proteomics:
40 691 Current trends and future perspectives for biomarker discovery. *Oncotarget* 2017;8:18497–18512.
41 692 doi:10.18632/oncotarget.14501.
- 43 693 [76] Kolonin M, Sergeeva A, Staquicini D, Molldrem JJ, Pasqualini R, Arap W. Neutrophil-Secreted Proteinase
44 694 3 Mediates Metastasis of Prostate Cancer Cells Expressing RAGE to the Bone Marrow. *Blood*
45 695 2016;128:1025–1025. doi:10.1182/blood.V128.22.1025.1025.
- 47 696 [77] Engers R, Ziegler S, Mueller M, Walter A, Willers R, Gabbert HE. Prognostic relevance of increased Rac
48 697 GTPase expression in prostate carcinomas. *Endocr Relat Cancer* 2007;14:245–256. doi:10.1677/ERC-06-
49 698 0036.
- 51 699 [78] Rodríguez-Berriguete G, Fraile B, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. MAP
52 700 Kinases and Prostate Cancer. *J Signal Transduct* 2012;2012:169170. doi:10.1155/2012/169170.

- 1
2
3 701 [79] Walker C, Mojares E, Del Río Hernández A. Role of extracellular matrix in development and cancer
4 702 progression. *Int J Mol Sci* 2018;19. doi:10.3390/ijms19103028.
- 6 703 [80] Antonopoulou E, Lodomery M. Targeting splicing in prostate cancer. *Int J Mol Sci* 2018;19.
7 704 doi:10.3390/ijms19051287.
- 9 705 [81] Culig Z, Santer FR. Androgen receptor signaling in prostate cancer. *Cancer Metastasis Rev* 2014;33:413–
10 706 427. doi:10.1007/s10555-013-9474-0.
- 12 707 [82] Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. *Cold Spring Harb Perspect Med*
13 708 2017;7. doi:10.1101/cshperspect.a030452.
- 15 709 [83] Belinky F, Nativ N, Stelzer G, Zimmerman S, Iny Stein T, Safran M, et al. PathCards: multi-source
16 710 consolidation of human biological pathways. *Database (Oxford)* 2015;2015.
18 711 doi:10.1093/database/bav006.
- 20 712 [84] Androgen receptor signaling pathway. PathCards Pathway Unification Database n.d.
21 713 https://pathcards.genecards.org/Card/androgen_receptor_signaling_pathway?queryString=ANDROGEN
22 714 (accessed October 14, 2019).
- 24 715 [85] Webber JP, Spary LK, Mason MD, Tabi Z, Brewis IA, Clayton A. Prostate stromal cell proteomics analysis
25 716 discriminates normal from tumour reactive stromal phenotypes. *Oncotarget* 2016;7:20124–20139.
26 717 doi:10.18632/oncotarget.7716.
- 28 718
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



203x101mm (300 x 300 DPI)